Form 4: BioLife Solutions Executive Aby J. Mathew Sells Shares Under 10b5-1 Trading Plan

Executive Vice President and Chief Scientific Officer of BioLife Solutions, Aby J. Mathew, executed multiple sales of company stock under a pre-arranged 10b5-1 trading plan.

Summary

• Aby J. Mathew, EVP & Chief Scientific Officer at BioLife Solutions, sold a total of 52,604 shares of common stock between November 15th and November 18th, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 14, 2024.
• On November 15th, 10,000 shares were acquired through the exercise of an employee stock option at a price of $2.06 per share.
• The same day, 10,000 shares were sold at a weighted average price of $21.16, and another 15,000 shares were sold at a weighted average price of $21.17.
• On November 18th, 17,604 shares were sold at a price of $20.05 per share.
• Following these transactions, Mathew directly owns 284,442 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't indicate positive or negative sentiment about the company's performance, but rather a routine disclosure of executive trading activity.

Risks

• Executive stock sales could be perceived negatively by the market, potentially impacting investor confidence.
• The use of a 10b5-1 trading plan suggests pre-planned sales, which may not reflect the executive's current outlook on the company's future.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice for executives to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly listed companies, and the use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
• Comparable companies in the biotechnology and life sciences sector often see similar filings from their executives.
• The volume of shares sold and the price range are within typical parameters for executive transactions.

Stakeholder Impact

• Shareholders may react to the news of executive stock sales, potentially leading to short-term price fluctuations.
• The impact on other stakeholders is likely to be minimal as this is a routine transaction.

Key Dates

Keywords

insider trading, stock sales, 10b5-1 plan, executive compensation, share transactions, BioLife Solutions, BLFS